skip to main content
Lingue:

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma

Bisogno, Gianni ; Ferrari, Andrea ; Prete, Arcangelo ; Messina, Chiara ; Basso, Eleonora ; Cecchetto, Giovanni ; Indolfi, Paolo ; Scarzello, Giovanni ; D'Angelo, Paolo ; De Sio, Luigi ; Di Cataldo, Andrea ; Carli, Modesto

European journal of cancer (Oxford, England : 1990), November 2009, Vol.45(17), pp.3035-41 [Rivista Peer Reviewed]

Fulltext disponibile

Citazioni Citato da
  • Titolo:
    Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma
  • Autore: Bisogno, Gianni ; Ferrari, Andrea ; Prete, Arcangelo ; Messina, Chiara ; Basso, Eleonora ; Cecchetto, Giovanni ; Indolfi, Paolo ; Scarzello, Giovanni ; D'Angelo, Paolo ; De Sio, Luigi ; Di Cataldo, Andrea ; Carli, Modesto
  • Note di contenuto: The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. Seventy patients were enrolled and received three cycles of initial standard chemotherapy, followed by a course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC), then three consecutive high-dose combinations followed by PBSC rescue. This was followed by surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosphamide was administered. Sixty-two patients underwent the high-dose chemotherapy phase. The 3-year overall survival (OS) and progression free survival (PFS) rates for the 70 patients were 42.3% (95% confidence interval [CI] 39.5-53.6) and 35.3% (95% CI, 24.3-46.5), respectively. By multivariate analysis survival correlated strongly with age > 10 years. In a subset of patients with only one or no unfavourable prognostic factors (age > 10 years, unfavourable site of primary tumour, bone or bone marrow involvement and number of metastatic sites >2) the PFS was significantly higher, i.e. 60.5% at 3 years. Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma.
  • Fa parte di: European journal of cancer (Oxford, England : 1990), November 2009, Vol.45(17), pp.3035-41
  • Soggetti: Antineoplastic Combined Chemotherapy Protocols -- Therapeutic Use ; Rhabdomyosarcoma -- Drug Therapy
  • Lingua: Inglese
  • Tipo: Articolo
  • Identificativo: E-ISSN: 1879-0852 ; PMID: 19783136 Version:1 ; DOI: 10.1016/j.ejca.2009.08.019
  • Fonte: MEDLINE/PubMed (U.S. National Library of Medicine)

Ricerca in corso nelle risorse remote ...